A quick glance at today's newsfeeds includes coverage of the Annual Health Datapalooza in Washington D.C. – a conference focused on "liberating health data, and bringing together the companies, startups, academics, government agencies, and individuals with the newest and most innovative and effective uses of health data to improve patient outcomes"; and Cigna announcing value-based contracts for a new class of cholesterol drugs ("Health Insurers Push to Tie Drug Prices to Outcomes," The Wall Street Journal, May 11, 2016). The Cigna deal will allow them to have access to, guess what, patient data to track whether these patients have heart attacks or other cardiovascular events (although this information will not effect reimbursement levels in the current contracts). In addition, a Cigna spokeswoman said "the company can monitor patients' adherence to prescriptions, side effects and drug interactions. The company also can review lab results and work with customers' doctors as needed, she said."
To continue reading, become an ALM digital reader
Benefits include:
- Complimentary access to Consulting Magazine Online and digital edition
- Bi-monthly digital newsletter delivered to your inbox
- 1 free article* every 30 days to Consulting Magazine's sister publications
- Exclusive discounts on events and publications produced by ALM
Already have an account? Sign In